Immunic (NASDAQ:IMUX - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Immunic Price Performance
IMUX stock opened at $1.15 on Monday. The company has a market capitalization of $103.59 million, a P/E ratio of -0.93 and a beta of 1.89. The company has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.24. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11.
Analyst Ratings Changes
Several equities research analysts recently weighed in on IMUX shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a report on Saturday, February 22nd. Finally, D. Boral Capital restated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $12.67.
View Our Latest Research Report on IMUX
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
